| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/30/2003 | US20030022929 Method of using soluble epoxide hydrolase inhibitors |
| 01/30/2003 | US20030022921 Stable pharmaceutical formulation comprising torsemide modification II |
| 01/30/2003 | US20030022914 Nitric oxide synthase inhibitors |
| 01/30/2003 | US20030022907 Anxiolytic agents and analgesics |
| 01/30/2003 | US20030022905 Prevention and/or therapy of ischaemia and reperfusion damage; poly(ADP-ribose)-synthetase inhibitors |
| 01/30/2003 | US20030022901 Serotonergic agents |
| 01/30/2003 | US20030022893 Hydroxamic and carboxylic acid derivatives |
| 01/30/2003 | US20030022891 Melanin-concentrating hormone (MCH); treating metabolic and eating disorders, such as hyperphagia, and diabetes; urea, thiourea and cyano-guanidine compounds of given formula |
| 01/30/2003 | US20030022890 Heterocyclic dihydropyrimidine compounds |
| 01/30/2003 | US20030022887 Unsymmetrical cyclic diamine compound |
| 01/30/2003 | US20030022885 Pyrazole compounds useful as protein kinase inhibitors |
| 01/30/2003 | US20030022883 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 01/30/2003 | US20030022875 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| 01/30/2003 | US20030022874 New 17-halogenated 19-nor steroids, preparation process and intermediates, use as medicaments and the pharmaceutical compositions containing them |
| 01/30/2003 | US20030022865 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 01/30/2003 | US20030022847 Administering antibiotics of quinolones, quinones, aminoglycosides or chloramphenicol to an individual under ischemic condition which lacks an adequate supply of oxygen and glucose |
| 01/30/2003 | US20030022840 Drugs for ameliorating impaired glucose tolerance |
| 01/30/2003 | US20030022828 A growth factor formulation comprising: a polypeptide of the TGF- beta (tranformation growth factor) superfamily, N-vinyl-2-pyrrolidone polymer carrier and a solvent selected from water and aqueous buffer solutions |
| 01/30/2003 | US20030022823 Glucagon-like peptide (GLP-1), an analog, or a derivative, is administered at a dose effective to normalize blood glucose after myocardial infarction in diabetic patients |
| 01/30/2003 | US20030022819 Administering to an animal an angiogenic amount of a hedgehog polypeptide or agonist to promote angiogenesis |
| 01/30/2003 | US20030022813 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022812 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022367 Cells for use as models in the treatment of heart defects |
| 01/30/2003 | US20030022366 Method for increasing survival rate of cells in animal cell culture under hypoxia condition |
| 01/30/2003 | US20030022354 Protein c derivatives |
| 01/30/2003 | US20030022338 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 01/30/2003 | US20030022211 Nucleotide sequences coding polypeptide for use in diagnosis and prevention of psychological and nervous system disorders |
| 01/30/2003 | US20030022209 ADSLs as modifiers of the p53 pathway and methods of use |
| 01/30/2003 | US20030022172 Polyamide nucleic acid derivatives and agents and processes for preparing them |
| 01/30/2003 | US20030022161 Diagnosing mammary gland cancer in humans; obtain ductal fluid sample, monitor marker gene product expression, amplified concentrations of marker products indicates cancer |
| 01/30/2003 | US20030021857 Plant extracts; viricides, blood flow, alopecia |
| 01/30/2003 | US20030021854 Nanocrystal microbiocide metal |
| 01/30/2003 | US20030021792 Quantitative analysis; immunosuppressants, anticoagulants |
| 01/30/2003 | US20030021787 In situ therapy; sustained release |
| 01/30/2003 | US20030021776 Regulation of angiogenesis with zinc finger proteins |
| 01/30/2003 | US20030021765 Polymer conjugates of interferon beta-1a and uses |
| 01/30/2003 | CA2470958A1 Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases |
| 01/30/2003 | CA2454427A1 A novel g protein-coupled receptor, gave8 |
| 01/30/2003 | CA2454418A1 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/30/2003 | CA2454335A1 Process for the preparation of citalopram hydrobromide |
| 01/30/2003 | CA2454187A1 Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
| 01/30/2003 | CA2454059A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 01/30/2003 | CA2454007A1 Tetrahydroquinoxalines acting as bradykinin antagonists |
| 01/30/2003 | CA2453986A1 Glycoprotein vi fusion proteins |
| 01/30/2003 | CA2453977A1 Stents with vitronectin receptor antagonists against restenosis |
| 01/30/2003 | CA2453967A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453965A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453765A1 Polysaccharidic esters of retinoic acid |
| 01/30/2003 | CA2453650A1 Substituted isoindoles and the use thereof |
| 01/30/2003 | CA2453633A1 Aryl substituted thiazolidinones and the use thereof |
| 01/30/2003 | CA2453613A1 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 01/30/2003 | CA2453602A1 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | CA2453478A1 Agent for treatment of cerebral ischemic diseases |
| 01/30/2003 | CA2453294A1 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | CA2452953A1 Stent vascular intervention device and method |
| 01/30/2003 | CA2452678A1 Combination of eplerenone and an hmg coa reductase inhibitor |
| 01/30/2003 | CA2452541A1 (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators |
| 01/30/2003 | CA2452357A1 Pharmaceutical formulation containing an ltb4 antagonist |
| 01/30/2003 | CA2452322A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/30/2003 | CA2452009A1 Chemical compounds |
| 01/30/2003 | CA2451530A1 Chemical compounds |
| 01/30/2003 | CA2451445A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 01/30/2003 | CA2450437A1 1-phenylsulphonyl-1,3-dihydro-2h-indol-2-one derivatives, their preparation and their therapeutic application |
| 01/30/2003 | CA2395992A1 Method for the screening of compounds that inhibit the interaction between a proline-rich peptide and a sh3 domain comprising peptide |
| 01/29/2003 | WO2002009713A2 Selective pde 2 inhibitors, used as medicaments for improving cognition |
| 01/29/2003 | EP1279666A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/29/2003 | EP1279406A1 Transporters and drug delivery system by using the same |
| 01/29/2003 | EP1279404A1 Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
| 01/29/2003 | EP1279400A1 Modifying the fatty acid composition of cell membranes of organs and tissues |
| 01/29/2003 | EP1279332A2 Transgenic non-human mammal |
| 01/29/2003 | EP1278893A2 Diagnosis of diseases associated with dna replication |
| 01/29/2003 | EP1278874A2 Hybrid protein and vector encoding the same for inhibition of angiogenesis |
| 01/29/2003 | EP1278870A1 Splice variant of camp phosphodiesterase type 7 (pde7a3) |
| 01/29/2003 | EP1278869A2 Proteases |
| 01/29/2003 | EP1278859A2 Human protein kinases and protein kinase-like enzymes |
| 01/29/2003 | EP1278846A2 Cytoskeleton-associated proteins |
| 01/29/2003 | EP1278838A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 01/29/2003 | EP1278774A2 Human g-protein coupled receptors |
| 01/29/2003 | EP1278770A1 Human wingless-like gene |
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278763A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
| 01/29/2003 | EP1278751A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists |
| 01/29/2003 | EP1278749A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 01/29/2003 | EP1278748A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 01/29/2003 | EP1278747A1 Pyrano, piperidino, and thiopyrano compounds and methods of use |
| 01/29/2003 | EP1278744A1 Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors |
| 01/29/2003 | EP1278739A1 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor |
| 01/29/2003 | EP1278734A2 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore |
| 01/29/2003 | EP1278732A1 1-aroyl-piperidinyl benzamidines |
| 01/29/2003 | EP1278729A1 Benzosuberonylpiperidine compounds as analgesics |
| 01/29/2003 | EP1278719A1 Naphthamide neurokinin antagonists for use as medicaments |
| 01/29/2003 | EP1278716A1 Cyclohexylamine derivative as subtype selective nmda receptor antagonists |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278543A2 Antibody binding alpha4beta7 integrin and its use to treat inflammatory bowel disease |
| 01/29/2003 | EP1278540A2 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 01/29/2003 | EP1278538A1 Cd18-binding antibodies inhibit stenosis-related disorders |
| 01/29/2003 | EP1278532A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses |
| 01/29/2003 | EP1278526A2 Treatment of cerebrovascular disease |
| 01/29/2003 | EP1278502A2 Protease inhibitors |
| 01/29/2003 | EP1278493A1 Apparatus and method for delivering compounds to a living organism |